Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aprepitant + Ondansetron for CINV in Glioma
NCT01450826Phase 2Completed
- Sponsor
- Katy Peters
- Start
- Jun 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of aprepitant in chemotherapy-induced nausea and vomiting (CINV) (2 arms), sponsored by Katy Peters. Primary endpoint: Proportion of Patients Achieving Complete Control at 7 days. Started Jun 2014; status: completed.
02
Drugs
aprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT01450826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01450826.